Oxford BioDynamics moves into new 24,000 sq ft tailor-made facility
to support ongoing growth

Change of registered office

Oxford, UK - 28 September 2021 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing targeted clinical diagnostic tests for immune health using its EpiSwitch® 3D genomics technology, has completed its move into its new purpose-built facility on the Oxford Business Park, essential to support the Company's ongoing growth and expanded strategic focus [1].

The Company's new 24,000 sq ft headquarters, first announced in April 2021 [2], offers a major step up in capacity from the former 6000 sq ft premises. The new office and state-of-the-art laboratory space will enable OBD to deliver its product and services offerings in a scalable way, including commercial test development and product support, biomarker discovery and drug development services, while also supporting clinical trials with pharma and academic research collaborations.

Dr Jon Burrows, CEO of Oxford BioDynamics, said: "With OBD's strong growth outlook, our move to this larger, purpose-built facility is key to the execution of our strategy. It is important in particular as we prepare for commercialization of EpiSwitch® CiRT - our Checkpoint Inhibitor Response Test for cancer - in Q4, and with respect to our recent FNIH PACT award [3]. These are linked to the immune-oncology interests of the pharma industry, which has generated significant attention, and we expect more activity from these groups.

"I would like to thank everyone who has worked to make our move so successful, particularly during continuing COVID-19 disruption."

OBD's registered office address has changed with immediate effect to 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, OX4 2WB, UK.

-Ends-

For more information:

Notes to Editors

About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. Its next product will be a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021. 

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.

About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

Oxford BioDynamics is leveraging its leading technology to develop a pipeline of tests in a wide range of indications, such as immuno-oncology, oncology, and veterinary medicine, to follow the release of its EpiSwitch® CST (Covid Severity Test).

 References

1.     RNS Press Release, Oxford BioDynamics to expand strategic focus beyond biomarker discovery to development and commercialization of laboratory tests, 15 Dec 2020.

2.     RNS Press Release, Oxford BioDynamics signs lease for new lab and office space at Oxford Business Park, supporting expanded strategy, 09 Apr 2021.

3.     RNS Press Release, Oxford BioDynamics awarded US FNIH Grant to apply EpiSwitch® Immune Health test for improved prediction of patient response to Immune Checkpoint Inhibitor (ICI) cancer therapies, 31 Aug 2021.